发明名称 |
Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
摘要 |
The present invention relates to a method for treating a cancer comprising orally administering a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment. |
申请公布号 |
USRE46284(E1) |
申请公布日期 |
2017.01.24 |
申请号 |
US201514985148 |
申请日期 |
2015.12.30 |
申请人 |
TAIHO PHARMACEUTICAL CO., LTD. |
发明人 |
Emura Tomohiro;Mita Akira |
分类号 |
A61K31/535;A61K31/513 |
主分类号 |
A61K31/535 |
代理机构 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
代理人 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
主权项 |
1. A method for treating at least one of a digestive cancer and a breast cancer, comprising
orally administering a composition comprising α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 50 to 70 mg/m2/day in terms of FTD in 2 or 3 divided portions per day to a human patient in need of treatment of at least one of a digestive cancer and a breast cancer, wherein the administration of a daily dose of said composition is in 2 or 3 portions per day for 5 days followed by 2 days off treatment in the week on a one-week dosing schedule wherein m2 is the human patient's body surface area. |
地址 |
Tokyo JP |